GenMark Diagnostics Inc

GenMark Diagnostics — Investor Presentation (June 2012)

20 slides from GenMark Diagnostics's investor presentation, Jun 20, 2012

  1. Slide 1: Management Presentation

    Management Presentation GenMark Diagnostics Multiplex tests. Personalized results. Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements about GenMark Diagnostics, Inc. These statements involve known and unknown risks that relate to the Company’s future events or future financial performance and the actual results could differ materially from those discu

  3. Slide 3: GenMark’s Solution

    GenMark’s Solution Standardized, Random Access, Scalable Amplified patient sample Add proprietary label Load mixture Patient results Insert cartridge

  4. Slide 4: GenMark Addressable Market

    GenMark Addressable Market Growth Drivers • Clinical need • Decentralization • Reimbursement Highest Growth • PGx ~30% • Oncology ~17% • ID ~14% Source: Decisive Bio-Insights 2012, LEK 2009, Management estimates Multiplex MDx Opportunity Current Global MDx market approximately $4.5B growing 15% $900

  5. Slide 5: Clinical Importance of Multiplex Testing

    Clinical Importance of Multiplex Testing Improving diagnosis of complex medical problems Viral diversity impacts therapy regimens Hepatitis C virus genotyping Multiple pathogens present similar symptoms Respiratory virus panel

  6. Slide 6: Core Technology

    Core Technology Electronic DNA detection Differentiating specificity & sensitivity $120M invested, 100+ U.S. patents Competitive Advantages True multiplexing Supports decentralization Provides cost advantages GenMark’s Technology

  7. Slide 7: Testing Standardization

    Testing Standardization • Single detection system for broad menu • Uniform assay procedures Laboratory Efficiency • Random & continuous access • No calibration or routine maintenance Accuracy & Performance • 100% accuracy & reproducibility • 30 minute processing Customer Value Proposition Sources: P

  8. Slide 8: XT-8 System ~1000 Post-PCR Labs

    XT-8 System ~1000 Post-PCR Labs Target Customers Management estimates subject to change. ~1,000 labs Limited MDx menu 500 full service MDx labs 35,000+ POLs ~5,000 labs No MDx menu

  9. Slide 9: Development

    Development Design Clinical trials / RUO product FDA cleared IVD product Thrombophilia Risk Test Warfarin Cystic Fibrosis Respiratory Viral Panel Plavix (2C19) HCV Genotyping Menu & Pipeline Pending FDA 510(k) clearance HCVg Direct KRAS Infectious Disease Pharmacogenetics Inherited Disease Oncology

  10. Slide 10: Low-plex vs Multiplex Competitive Positioning

    Low-plex Multiplex Centralized Decentralized Fragmented Competition Increasing Emphasis on Multiplex IVD MDx Companies listed are representative. Positioning reflects management’s current opinion and is subject to change.

  11. Slide 11: NexGen System

    NexGen System The all-digital, sample-to-answer system • Fully integrated Extraction to result • “Electrowetting” fluidics No channels, valves or pumps • Rapid configuration Software vs hardware • Low cost High profit margins Management estimates subject to change.

  12. Slide 12: NexGen System (cont’d)

    NexGen System (cont’d) The all-digital, sample-to-answer system • Core detection technology designed to ensure accuracy & quality of results • Fully-integrated cartridge delivers superior ease of use • Provides flexibility with menu and sample types Decentralization today POC testing tomorrow Manage

  13. Slide 13: NexGen Test Menu Opportunities

    Low-plex Tests (<5 targets) Multiplex Tests (10+ targets) Market Opportunity Customer Issue NexGen Test Menu Opportunities Addressing a significant unmet need • >$1B global market with established test volumes • Tests include MRSA, C. Diff, CT/NG • Limited platform and menu options today for decentr

  14. Slide 14: NexGen Menu Opportunities

    XT-8 NexGen Menu Opportunities Technology enabled consolidation of testing Infectious Disease Pharmacogenetics Inherited Disease Oncology Management estimates subject to change. Gastrointestinal Infections (Bacterial, Viral…) Oncology (KRAS, EGFR…) Blood Culture ID PGx (Warfarin, 2C19…) HAI (MRSA, C

  15. Slide 15: NexGen System Sample-to-Answer 5,000+ labs

    NexGen System Sample-to-Answer 5,000+ labs ~1,000 labs Limited MDx menu 500 full service MDx labs 35,000+ POLs ~5,000 labs No MDx menu Target Customers NexGen dramatically expands customer base Management estimates subject to change.

  16. Slide 16: Attractive Business Model

    CF TRT Warfarin Plavix (2C19) RVP HCVg KRAS HCVg Direct Attractive Business Model Razor/Razor Blade “Razor” “Razor Blades” FDA Approved Tests RUO/Clinical Trial Tests Tests In Development Increased test utilization will be key revenue driver Infectious Disease Pharmacogenetics Inherited Disease Onco

  17. Slide 17: “Tat

    250 200 150 100 50 “Tat 2009 = Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 @ Existing Analyzer Installed Base ld Net New Analyzer Placements. ATP NAD GenMarkpx

  18. Slide 18: Executing on Business Model

    Executing on Business Model Delivering value to customers & shareholders Management estimates subject to change.

  19. Slide 19: Key Milestones

    Key Milestones Strong execution history Management estimates subject to change. • Nasdaq IPO • Established direct sales force • Launched TRT as IVD • Launched RVP as RUO • Launched 2C19 as RUO • Initiated RVP clinical studies • Relocated to Carlsbad • Submitted RVP to FDA • Launched HCVg as RUO • Co

  20. Slide 20: Key Milestones: 2012 Priorities

    Key Milestones 2012 priorities Management estimates subject to change. Product Development Commercialization • Launch RVP IVD • Launch HCVg Direct RUO • Initiate 2C19 clinical trial • Expand test menu • NexGen development • Place 100+ analyzers • Drive annuity per analyzer • Expand sales force • Ini

GenMark Diagnostics — Investor Presentation (June 2012) on 6ix